If your high-tech stocks have stalled and your portfolio is aching, you might try a little gene therapy. With the recent completion of the mapping of the human genome, as well as changes in federal drug-approval policy, the biotechnology sector is again enjoying the meteoric rises it experienced in the late 1980s. It has about 2,000 subscribers, a 50-50 mix of individuals and institutions. And today, she says, biotech is the place to be. The sector has matured.
Management is more experienced and smarter.
She believes that genomics has put the biotech business where the computer industry was 30 years ago. The Portland, Ore., editor shared her enthusiasm for some new drugs on the market, discussed several compelling biotech initial public offerings and told us why this will continue to be a banner year for biotechs. A catalyst for the biotech industry Your newsletter is considered one of the leading authorities in the biotech sector. We publish the Biotech Sage Report monthly, and we're targeting investors who are very serious about the biotech sector. Every month, we focus on a different topic.